Parkman Healthcare Partners LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Parkman Healthcare Partners LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 41.5% in the 4th quarter, HoldingsChannel reports. The firm owned 37,472 shares of the biotechnology company’s stock after selling 26,559 shares during the period. United Therapeutics makes up about 1.8% of Parkman Healthcare Partners LLC’s holdings, making the stock its 19th largest holding. Parkman Healthcare Partners LLC’s holdings in United Therapeutics were worth $13,222,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 30.4% in the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $4,098,000 after purchasing an additional 2,702 shares in the last quarter. Milestone Asset Management LLC raised its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares during the last quarter. Korea Investment CORP boosted its holdings in United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock valued at $13,863,000 after acquiring an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after acquiring an additional 789 shares during the last quarter. Finally, Burney Co. increased its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after purchasing an additional 12,705 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.9%

Shares of NASDAQ:UTHR opened at $308.07 on Wednesday. United Therapeutics Co. has a fifty-two week low of $264.33 and a fifty-two week high of $417.82. The company has a market cap of $13.90 billion, a PE ratio of 13.53, a P/E/G ratio of 0.97 and a beta of 0.58. The firm has a 50-day simple moving average of $300.54 and a 200 day simple moving average of $341.52.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. During the same quarter in the previous year, the business posted $6.17 EPS. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. As a group, research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective for the company in a report on Monday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $392.00.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. This trade represents a 79.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now owns 36,781 shares in the company, valued at $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,500 shares of company stock valued at $20,765,280. 11.90% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.